Examkin

Question

Difficulty: HardMust Be True / Most Strongly Supported

Every monoclonal antibody treatment approved by the Federal Health Directorate for autoimmune disorders must either undergo a specialized glycosylation assay or be synthesized exclusively via mammalian expression vectors. No pharmaceutical candidate synthesized exclusively via mammalian expression vectors is exempt from cold-chain temperature logging during cross-border transit. Furthermore, any therapeutic agent subjected to the specialized glycosylation assay exhibits batch-to-batch molecular homogeneity. Nexovira is a monoclonal antibody treatment approved by the Federal Health Directorate for autoimmune disorders that is exempt from cold-chain temperature logging during cross-border transit.

If the statements above are true, which one of the following must also be true on the basis of them?

  1. A
    If a pharmaceutical candidate is not exempt from cold-chain temperature logging during cross-border transit, it was synthesized exclusively via mammalian expression vectors.
  2. B
    No drug approved by the Federal Health Directorate for autoimmune disorders is synthesized exclusively via mammalian expression vectors.
  3. Nexovira exhibits batch-to-batch molecular homogeneity.Answer
  4. D
    Nexovira provides greater clinical efficacy for rheumatoid arthritis than any monoclonal antibody treatment that requires cold-chain temperature logging.
  5. E
    Any therapeutic agent that exhibits batch-to-batch molecular homogeneity has undergone a specialized glycosylation assay.

Answer

Nexovira exhibits batch-to-batch molecular homogeneity.
The stimulus establishes that Nexovira is an approved autoimmune monoclonal antibody treatment that is exempt from transit cold-chain temperature logging. Because synthesis via mammalian expression vectors strictly precludes cold-chain exemptions, Nexovira's exemption guarantees via contrapositive that it was not synthesized via mammalian vectors. Consequently, under the Directorate's approval rule, Nexovira must have undergone the specialized glycosylation assay. Since undergoing this assay guarantees batch-to-batch molecular homogeneity, Nexovira must possess this characteristic.

Step-by-Step Solution

1
Diagram the formal conditional rules and relationships given in the stimulus.
Approved Treatment → (Glycosylation Assay OR Mammalian Vectors); Mammalian Vectors → NOT Exempt from cold-chain logging; Glycosylation Assay → Molecular Homogeneity.
Establishing explicit conditional chains allows for accurate multi-step deduction.
2
Apply the contrapositive of the cold-chain transit rule to the factual profile of Nexovira.
Because Nexovira is exempt from cold-chain logging, it was NOT synthesized exclusively via mammalian expression vectors.
If a necessary condition is negated, the sufficient condition must also be negated.
3
Evaluate the disjunctive requirement for approved autoimmune treatments and trace the resulting implication.
Since Nexovira is an approved treatment but did not use mammalian expression vectors, it must have undergone the glycosylation assay, which in turn guarantees batch-to-batch molecular homogeneity.
Eliminating one branch of an 'either/or' requirement strictly necessitates the truth of the remaining branch.

Key Concept

Deductive Conditional Chaining and Disjunctive Syllogism
Estimated Time:2m 0s
Rate this question

Topics

Must Be True / Most Strongly Supported

More questions from this topic